| |
Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
Opexa Therapeutics (NASDAQ: OPXA), a biotechnology company developing Tcelna (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug Administration (FDA).
|
Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
Opexa Therapeutics (NASDAQ: OPXA), a biotechnology company developing Tcelna (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today disclosed that the Company has commenced development in a second indication, Neuromyelitis optica (NMO). NMO is a rare autoimmune disorder, which is designated as an Orphan disease by the U.S. Food and Drug Administration (FDA).
|
The Money Report | Air Dates
|
 |
Newsmax TV
Available 24 hrs
|
 |
Bloomberg Europe
Sundays 8:30 a.m. & 3:30 p.m. GMT
|
|
Bloomberg Asia
Sundays 3:30 p.m. HKT
|
 |
YouTube Channel
Available 24 hrs
|
Upcoming Events
[Short Description or Tagline]
RedChip Conferences
Mark your Calendars for the Next RedChip Global Online CEO Conference
January 28- 29
See Details »
OxySure Systems, Inc. (OTCQB: OXYS) investor webinar
OxySure Systems, Inc. (OTCQB: OXYS) is hosting an investor webinar
December 30, 2014, at 4:10 p.m. ET. CEO Julian Ross
See Details »
|
Quote of the Week
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
|
 |
Insider Buying Report
$1B and Under Market Cap
|
 |
Commodities Report
[text here]
|
 |
MidSouth Week in Review
Weekly Update from Fund Manager Buzz Heidtke, MidSouth Investment Fund
|
 |
Weekly Notes from Paul Resnik
Paul Resnik operates Resnik Asset Management Co. (RAMCO), a registered investment advisor.
|
Top Performers
| Company |
Current
Price |
Current
%Gained |
Highest
%Gained |
Quadrant 4 Systems
(OTC QB: QFOR) |
$0.06 |
725% |
2,200% |
Quadrant 4 Systems
(OTC QB: QFOR) |
$0.06 |
725% |
2,200% |
Quadrant 4 Systems
(OTC QB: QFOR) |
$0.06 |
725% |
2,200% |
Quadrant 4 Systems
(OTC QB: QFOR) |
$0.06 |
725% |
2,200% |
Quadrant 4 Systems
(OTC QB: QFOR) |
$0.06 |
725% |
2,200% |
*as of 12/30/2014
Research Reports
The only ECO MR pure play in the market
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
j2 Global Inc. (Nasdaq: JCOM)
|
|
See Report »
|
Strong financial position with positive guidance outlook
j2 Global Inc. (Nasdaq: JCOM)
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
|
|
See Report »
|
|
